TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zomedica ( (ZOMDF) ) has provided an update.
On June 10, 2025, Zomedica held its annual shareholder meeting where three key proposals were voted on. Shareholders approved the election of eight directors and the ratification of Grant Thornton LLP as the independent auditor for 2025, but did not approve the executive compensation package.
The most recent analyst rating on (ZOMDF) stock is a Buy with a $0.25 price target. To see the full list of analyst forecasts on Zomedica stock, see the ZOMDF Stock Forecast page.
Spark’s Take on ZOMDF Stock
According to Spark, TipRanks’ AI Analyst, ZOMDF is a Neutral.
Zomedica’s stock score reflects mixed financial performance with revenue growth but persistent profitability challenges. The technical analysis shows weak momentum, and the valuation is impacted by a negative P/E ratio. Despite strong earnings call highlights, increased net loss and delisting risks present concerns.
To see Spark’s full report on ZOMDF stock, click here.
More about Zomedica
Average Trading Volume: 2,393,495
Technical Sentiment Signal: Sell
Current Market Cap: $42.63M
See more insights into ZOMDF stock on TipRanks’ Stock Analysis page.